A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-small-cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Overview

Journal J Thorac Oncol

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2014 Jan 15

PMID 24419411

Citations 761

Authors

Yuankai Shi

Joseph Siu-Kie Au

Sumitra Thongprasert

Sankar Srinivasan

Chun-Ming Tsai

Mai Trong Khoa

Karin Heeroma

Yohji Itoh

Gerardo Cornelio

Pan-Chyr Yang

Affiliations

Soon will be listed here.

Abstract

Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly diagnosed advanced lung adenocarcinoma.

Methods: Eligible patients (aged ≥20 years) had untreated stage IIIB/IV adenocarcinoma. The EGFR mutation status (primary end point: positive, negative, or undetermined) of tumor samples (biopsy, surgical specimen, or cytology) was determined (Scorpion amplification refractory mutation system). EGFR mutation frequency was calculated and compared between demographic and clinical subgroups.

Results: Of 1482 patients from seven Asian regions, 43.4% of patients were female, median age was 60 years (range, 17-94), and 52.6% of patients were never-smokers. EGFR mutation status was evaluable in tumors from 1450 patients (97.8%) (746 [51.4%] positive; 704 [48.6%] negative). Country, sex, ethnicity, smoking status, pack-years (all p < 0.001), disease stage (p = 0.009), and histology type (p = 0.016) correlated significantly with EGFR mutation frequency. Mutation frequency was 61.1% in females, 44.0% in males; lower in patients from India (22.2%) compared with other areas (47.2%-64.2%); highest among never-smokers (60.7%); and decreased as pack-year number increased (>0-10 pack-years, 57.9%; >50 pack-years, 31.4%) (similar trend by sex). Ethnic group (p < 0.001) and pack-years (p < 0.001) had statistically significant associations with mutation frequency (multivariate analysis); sex was not significant when adjusted for smoking status.

Conclusion: PIONEER is the first prospective study to confirm high EGFR mutation frequency (51.4% overall) in tumors from Asian patients with adenocarcinoma. The observed high mutation frequency in demographic/clinical subgroups compared with white populations suggests that mutation testing should be considered for all patients with stage IIIB/IV adenocarcinoma, even males and regular smokers, among Asian populations.

Citing Articles

Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line.

Tang H, Chai C, Miao X, Su Y, Yu C, Yi J BMC Cancer. 2025; 25(1):472.

PMID: 40087624 DOI: 10.1186/s12885-025-13876-9.

Proteogenomic characterization reveals tumorigenesis and progression of lung cancer manifested as subsolid nodules.

Su H, Chen L, Wu J, Cheng Z, Li J, Ren Y Nat Commun. 2025; 16(1):2414.

PMID: 40069142 PMC: 11897189. DOI: 10.1038/s41467-025-57364-x.

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques.

Qi W, Tian L, Xu J, Li Z, Wang T Cancer Manag Res. 2025; 17:461-481.

PMID: 40060704 PMC: 11889406. DOI: 10.2147/CMAR.S506630.

Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives.

Li M, Mok K, Chan L, Mok T J Liq Biopsy. 2025; 3:100131.

PMID: 40026566 PMC: 11863888. DOI: 10.1016/j.jlb.2023.100131.

Cancer brain metastasis: molecular mechanisms and therapeutic strategies.

Lu Y, Huang Y, Zhu C, Li Z, Zhang B, Sheng H Mol Biomed. 2025; 6(1):12.

PMID: 39998776 PMC: 11861501. DOI: 10.1186/s43556-025-00251-0.

References

Azzoli C, Baker Jr S, Temin S, Pao W, Aliff T, Brahmer J . American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(36):6251-66. PMC: 2793036. DOI: 10.1200/JCO.2009.23.5622. View

Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K . EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 2005; 11(8):2924-9. DOI: 10.1158/1078-0432.CCR-04-1904. View

Wu Y, Zhong W, Li L, Zhang X, Zhang L, Zhou C . Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007; 2(5):430-9. DOI: 10.1097/01.JTO.0000268677.87496.4c. View

Sekine I, Yamamoto N, Nishio K, Saijo N . Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008; 99(11):1757-62. PMC: 2600690. DOI: 10.1038/sj.bjc.6604721. View

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

Saijo N, Takeuchi M, Kunitoh H . Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol. 2009; 6(5):287-94. DOI: 10.1038/nrclinonc.2009.37. View

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10):958-67. DOI: 10.1056/NEJMoa0904554. View

Choi Y, Sun J, Cho J, Rampal S, Han J, Parasuraman B . EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One. 2013; 8(2):e56011. PMC: 3585299. DOI: 10.1371/journal.pone.0056011. View

10.

Salto-Tellez M, Tsao M, Shih J, Thongprasert S, Lu S, Chang G . Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011; 6(10):1663-9. DOI: 10.1097/JTO.0b013e318227816a. View

11.

Leary A, Gonzalez de Castro D, Nicholson A, Ashley S, Wotherspoon A, OBrien M . Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer. 2011; 48(1):61-7. DOI: 10.1016/j.ejca.2011.09.022. View

12.

Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T . An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 2012; 23(11):2914-2919. DOI: 10.1093/annonc/mds121. View

13.

Lindeman N, Cagle P, Beasley M, Chitale D, Dacic S, Giaccone G . Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular.... J Thorac Oncol. 2013; 8(7):823-59. PMC: 4159960. DOI: 10.1097/JTO.0b013e318290868f. View

14.

Kawaguchi T, Matsumura A, Fukai S, Tamura A, Saito R, Zell J . Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization.... J Thorac Oncol. 2010; 5(7):1001-10. DOI: 10.1097/JTO.0b013e3181e2f607. View

15.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

16.

Fukuoka M, Wu Y, Thongprasert S, Sunpaweravong P, Leong S, Sriuranpong V . Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(21):2866-74. DOI: 10.1200/JCO.2010.33.4235. View

17.

Saijo N, Fukuoka M, Thongprasert S, Ichinose Y, Mitsudomi T, Mok T . Lung cancer working group report. Jpn J Clin Oncol. 2010; 40 Suppl 1:i7-12. DOI: 10.1093/jjco/hyq121. View

18.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

19.

Han J, Park K, Kim S, Lee D, Kim H, Kim H . First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30(10):1122-8. DOI: 10.1200/JCO.2011.36.8456. View

20.

Neal J, Sequist L . First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol. 2010; 8(2):119-26. View